Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease - Top-Institutions - MDSpire

Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease

  • By

  • Lizhen Li

  • Xiaolin Zhao

  • Li Zeng

  • Zixuan Li

  • Kaiyue Zhao

  • Zhongdi Cai

  • Rui Liu

  • May 4, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital and Brigham and Women’s Hospital (Mass General Brigham)
    Massachusetts General Hospital and Brigham and Women’s Hospital (Mass General Brigham)

    Boston, Massachusetts

    Key Differentiators

    • Neurology
    • Neurosurgery

  • #2

    University of California, San Francisco (UCSF) Memory and Aging Center
    University of California, San Francisco (UCSF) Memory and Aging Center

    San Francisco, California

    Key Differentiators

    • Neurology
    • Neuroscience

Original Source(s)

Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease

  • by Lizhen Li, Xiaolin Zhao, Li Zeng, Zixuan Li, Kaiyue Zhao, Zhongdi Cai, Rui Liu

  • May 4, 2026

Related Content

Ferroptosis-immune crosstalk in CNS diseases: mechanisms and translational insights

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

Synergistic effect between cortical cerebral microinfarcts and brain atrophy on cognitive decline